Form 4 for PRLD Prelude Therapeutics Inc
Accepted 2025-03-27 00:00:00 ET · period of report 2025-03-25 · accession 0001562180-25-002779 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-27 | 2025-03-25 | PRLD | Combs Andrew | Chief Chemistry Off | P - Purchase | $0.69 | +100.0K | 480.1K | +26% | +$69.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-25 | P | A | 100,000 | $0.69 | 480,123 | D | — | — | (F1) The reported total includes 2,500 shares of common stock the reporting person has acquired since the date of his last ownership report through the issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c). |